<DOC>
	<DOC>NCT01760122</DOC>
	<brief_summary>This study is aimed to assess the efficacy and safety of Peginterferon alfa-2b (40kD, Y-shape), in a dose of 180μg/week, in chronic hepatitis B patients, and collects sufficient evidences for the listed of the studied drug.</brief_summary>
	<brief_title>Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Age: 18~65 years. Serum HBsAg or HBV DNA positive for at least 6 months. Serum HBsAg and HBeAg are both positive, HBV DNA ≥ 20,000IU/ml at screening. 2×ULN≤ ALT ≤10×ULN at screening (ULN=upper limit of normal). Pregnancy tests of female patients must be negative. All patients with effective birth control measures during treatment period and 6 months after the treatment. Pregnant or lactating women. Mental disorder or physical disability. Interferon treatment history or using nucleos(t)ide analogue for chronic hepatitis B treatment within the previous 6 months. ANC &lt; 1500/mm3, or PLT &lt; 90,000/mm3. Coinfection with HAV, HIV, HCV, HDV, or HEV. Both of HBsAg and antiHBs are positive, or both of HBeAg and antiHBe are positive at screening. ChildPugh ≥ B, or other evidence of hepatitis decompensation (e.g.: prothrombin time prolonged more than 3 seconds, TBil &gt; 2ULN, Alb&lt;35g/L). Chronic hepatitis caused by any other reason except hepatitis B. Hepatocarcinoma or suffering from any other malignant tumor. Not wellcontrolled endocrine diseases (e.g.: thyroid dysfunction, diabetes mellitus) Significant function damage in any major organs (e.g.: heart, lung, kidney). Other Conditions which in the opinion of the investigator precluding enrollment into the study (e.g.: poor compliance).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>peginterferon</keyword>
	<keyword>HBeAg Positive</keyword>
	<keyword>Chronic hepatitis B</keyword>
</DOC>